Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of CVP-NASVAC therapeutic HBV vaccine in chronic hepatitis B under nucleos(t)ide analogue treatment
jRCTs061210086Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing CVP-NASVAC arm with Placebo arm (2 arms). Primary endpoints: HBsAg reduction and HBsAg loss rate. Started Jul 2022; status: recruiting.
02
Drugs
ABX203
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCTs061210086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210086.